Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5‑fluorouracil‑based chemotherapy

Kim,Kwan  Woo; Kwon,Hyuk‑Chan; Kim,Sung‑Hyun; Oh,Sung  Yong; Lee,Suee; Lee,Ji  Hyun; Roh,Myung   Hwan; Kim,Min  Chan; Kim,Ki  Han; Kim,Young  Hoon; Roh,Young   Hoon; Jeong,Jin   Sook; Kim,Hyo‑Jin

doi:10.3892/mco.2013.166

Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5‑fluorouracil‑based chemotherapy

Authors:
- Kwan Woo Kim
- Hyuk‑Chan Kwon
- Sung‑Hyun Kim
- Sung Yong Oh
- Suee Lee
- Ji Hyun Lee
- Myung Hwan Roh
- Min Chan Kim
- Ki Han Kim
- Young Hoon Kim
- Young Hoon Roh
- Jin Sook Jeong
- Hyo‑Jin Kim
View Affiliations

Affiliations: Department of Surgery, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Republic of Korea, Department of Internal Medicine, College of Medicine, Dong‑A University, Busan, Republic of Korea, Department of Surgery, College of Medicine, Dong‑A University, Busan, Republic of Korea, Department of Pathology, College of Medicine, Dong‑A University, Busan, Republic of Korea
Published online on: August 6, 2013 https://doi.org/10.3892/mco.2013.166
Pages: 987-994

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Biliary tract cancer (BTC) is a relatively uncommon type of cancer, accounting for ~4% of the malignant neoplasms of the gastrointestinal tract. The aim of this study was to determine whether the expression of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) predict clinical outcome in BTC patients treated with adjuvant 5‑fluorouracil (5‑FU)‑based chemotherapy. TS and TP expression were found to be significantly correlated with cancer location (P=0.044 and 0.031, respectively). The multivariate analysis revealed that age [hazard ratio (HR)=2.157, P=0.008], stage (HR=2.234, P<0.001), resection margin status (HR=2.748, P=0.004) and TP expression (HR=2.014, P=0.039) were independently associated with overall survival (OS).

View Figures

View References

1.	de Groen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med. 341:1368–1378. 1999.
2.	Jung KW, Park S, Kong HJ, et al: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 44:11–24. 2012. View Article : Google Scholar : PubMed/NCBI
3.	Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M and Nagakawa T: Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 16:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Horgan AM, Amir E, Walter T and Knox JJ: Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 30:1934–1940. 2012. View Article : Google Scholar : PubMed/NCBI
5.	Cereda S, Belli C and Reni M: Adjuvant treatment in biliary tract cancer: to treat or not to treat? World J Gastroenterol. 18:2591–2596. 2012. View Article : Google Scholar : PubMed/NCBI
6.	Takada T, Amano H, Yasuda H, et al: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 95:1685–1695. 2002. View Article : Google Scholar
7.	Neoptolemos JP, Moore MJ, Cox TF, et al: Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 308:147–156. 2012. View Article : Google Scholar
8.	Namwat N, Amimanan P, Loilome W, et al: Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines. Chemotherapy. 54:343–351. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Yamada H, Iinuma H and Watanabe T: Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes’ stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. Oncol Rep. 19:729–735. 2008.PubMed/NCBI
10.	Soong R, Shah N, Salto-Tellez M, et al: Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 19:915–919. 2008. View Article : Google Scholar
11.	Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Marsh S and McLeod HL: Cancer pharmacogenetics. Br J Cancer. 90:8–11. 2004. View Article : Google Scholar
13.	Popat S, Matakidou A and Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 22:529–536. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Kim JS, Kim MA, Kim TM, et al: Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer. 100:732–738. 2009.
15.	Kwon HC, Roh MS, Oh SY, et al: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 18:504–509. 2007. View Article : Google Scholar
16.	Takebe N, Xu LC, MacKenzie KL, Bertino JR and Moore MA: Methotrexate selection of long-term culture initiating cells following transduction of CD34⁺ cells with a retrovirus containing a mutated human dihydrofolate reductase gene. Cancer Gene Ther. 9:308–320. 2002. View Article : Google Scholar : PubMed/NCBI
17.	Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 6:1322–1327. 2000.
18.	Hasegawa S, Seike K, Koda K, et al: Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. Oncol Rep. 13:621–626. 2005.PubMed/NCBI
19.	Brown NS and Bicknell R: Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J. 334(Pt 1): 1–8. 1998.PubMed/NCBI
20.	Takebayashi Y, Akiyama S, Akiba S, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst. 88:1110–1117. 1996. View Article : Google Scholar
21.	Diasio RB and Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 16:215–237. 1989. View Article : Google Scholar
22.	Johnston PG, Drake JC, Trepel J and Allegra CJ: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 52:4306–4312. 1992.
23.	Edler D, Kressner U, Ragnhammar P, et al: Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res. 6:488–492. 2000.PubMed/NCBI
24.	Lenz HJ, Hayashi K, Salonga D, et al: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res. 4:1243–1250. 1998.PubMed/NCBI
25.	Soong R and Diasio RB: Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics. 6:835–847. 2005. View Article : Google Scholar : PubMed/NCBI
26.	Moghaddam A, Zhang HT, Fan TP, et al: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA. 92:998–1002. 1995. View Article : Google Scholar : PubMed/NCBI
27.	O’Brien TS, Fox SB, Dickinson AJ, et al: Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res. 56:4799–4804. 1996.PubMed/NCBI